Patents by Inventor Norbert Birk

Norbert Birk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORM OF AN MDM2-p53 INHIBITOR AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20240217985
    Abstract: The present invention relates to a crystalline form of an MDM2-p53 inhibitor and methods for its preparation. Furthermore, the invention relates to pharmaceutical compositions comprising an MDM2-p53 inhibitor, preferably the crystalline form of the present invention, and at least one pharmaceutically acceptable excipient as well as to methods for their preparation. The crystalline form of the MDM2-p53 inhibitor of the present invention and the pharmaceutical compositions of the present invention can be used as a medicament, in particular for the treatment of cancer in patients bearing tumors with TP53 wild-type status.
    Type: Application
    Filed: December 21, 2023
    Publication date: July 4, 2024
    Inventors: Fredrik Lars NORDSTROM, Norbert BIRK, Manuel HENRY, Brian J. LINEHAN, Peter SCHNEIDER
  • 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
    Patent number: 7141667
    Abstract: The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one of formula which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral treatment of migraine.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: November 28, 2006
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Schnaubelt, Werner Rall, Rainer Soyka, Norbert Birk, Ludwig Gutschera, Heidelore Heimroth, Thomas Krueger, Armin Proell
  • 3-(4-Piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
    Publication number: 20060019946
    Abstract: The present invention relates to a process for preparing the compound 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1-one of formula which is to be found as a structural element in CGRP-antagonists, which are particularly suitable for the oral treatment of migraine.
    Type: Application
    Filed: July 19, 2005
    Publication date: January 26, 2006
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Juergen Schnaubelt, Werner Rall, Rainer Soyka, Norbert Birk, Ludwig Gutschera, Heidelore Heimroth, Thomas Krueger, Armin Proell